Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Tables)

v3.24.1
Stockholders Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Stockholders Equity [Abstract]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders As of December 31, 2023, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:
Warrant   Issuance Date   Expiration
Date		   Exercise
Price
Per Share		     Number of
Shares of
Common Stock
Underlying
Warrants		  
Public Warrants   IPO (December 13, 2018)   October 28, 2024     11.50       3,500,000  
2021 Registered Direct Offering Warrants   SPA (July 28, 2021)   January 28, 2027     5.00       2,812,501  
Pre-Funded Warrants   February 27, 2023  
-
     0.001       2,776,428  
Pre-Funded Warrants   May 4, 2023  
-
     0.001       11,834,286  
                      20,923,215  
Schedule of Black-Scholes Option-Pricing Model The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model using the following assumptions:
    2023     2022  
             
Underlying value of Common Stock ($)     0.28-0.40       0.37-1.41  
Exercise price ($)     0.28-0.40       0.37-1.41  
Expected volatility (%)     90.0-96.6       85.3-88.4  
Expected terms of the option (years)     6.11       5.31-6.11  
Risk-free interest rate (%)     4.21-4.98       2.50-4.05  

 
Schedule of Options Granted to Purchase A summary of options granted to purchase the Company’s Common Stock under the Company’s stock option plans are as follows:
    For year ended
December 31, 2023		  
    Number of
Options		     Weighted
average
exercise
price		     Aggregate
intrinsic
value		  
                   
Outstanding at the beginning of period     4,769,441     $ 2.93     $ 40  
Granted     1,817,100       0.36          
Forfeited/canceled     (1,838,140 )     3.98          
Replacement options granted     694,871       0.27          
Expired     (162,561 )     4.66          
Exercised    
-
     $
-
          
Outstanding at the end of period     5,280,711       0.54     $ 72  
Exercisable at end of period     2,790,269       0.58          
Weighted average remaining contractual life – years as of December 31, 2023     6.85                  
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock As of December 31, 2023, and 2022, the Company had the following outstanding compensation related warrants to purchase Common Stock as follows:
Warrant   Issuance
Date		    Expiration
Date		    Exercise
Price
Per
Share    		      Number of
Shares of
Common
Stock
Underlying
Warrants  		  
Private Warrants issued to scientific founders (see below)    November 27, 2017  
-
    
-
       2,974  

  
Schedule of Stock-Based Payment Expenses The following table sets forth the total stock-based payment expenses resulting from options and warrants granted, included in the statements of operations:
    Year ended
December 31,		  
    2023     2022  
             
Research and development expenses, net     369       490  
General and administrative     690       1,039  
      1,059       1,529